AgomAb shared what it took to get a European biotech ready for a public-market launch, describing its pathway to an IPO and funding strategy for ontunisertib, an oral, GI-restricted ALK5 inhibitor for fibrostenosing Crohn’s disease. The company priced its Nasdaq IPO at $16, raising $200 million, and said it spent roughly two years preparing across logistical and legal requirements. AgomAb also described prior private rounds, including a $100 million Series C and an $89 million Series D with Sanofi participating, framing pharma interest as both financing and knowledge input. For investors and operating teams, the disclosure is a rare view into how modality and data readiness are packaged for public scrutiny in the current market window.